Target intelligence / Profile preview

CFTR antisense RNA 1 (CFTR-AS1)

Target
CFTR-AS1
Molecular classification
Long non-coding RNA (lncRNA), Regulatory RNA, Other (not a protein, not an enzyme, receptor, or ion channel—specifically a gene-regulatory lncRNA)
01

Overview

CFTR antisense RNA 1 (CFTR-AS1, also known as BGas) is a long non-coding RNA (lncRNA) transcribed in the antisense orientation from within intron 11 of the CFTR gene. BGas/CFTR-AS1 is approximately 3,944 nucleotides in length and is localized in the nucleus. It interacts with chromatin remodeling proteins (such as HMGA1, HMGB1, and WIBG) at the CFTR gene locus, where it modulates local chromatin structure and inhibits CFTR gene transcription by disrupting RNA polymerase II function. This results in decreased CFTR mRNA and protein levels, ultimately reducing CFTR chloride channel activity. Targeting CFTR-AS1 with antisense oligonucleotides (ASOs) can downregulate this lncRNA, enhance CFTR transcription, and restore protein function, suggesting potential as a therapeutic strategy for cystic fibrosis by increasing endogenous CFTR expression[2].

Other names
BGasB GasCFTR-AS1
02

Mechanism of action

Antisense oligonucleotide binding to CFTR-AS1, leading to RNase H-mediated degradation of the RNA, which enhances CFTR gene transcription and protein expression by removing the inhibitory effect of CFTR-AS1 on the CFTR gene

03

Biological functions

Regulation of gene expressionModulation of transcriptionChromatin remodelingRegulation of CFTR mRNA and protein levels
04

Disease associations

Cystic fibrosis (CF) (due to its regulatory action on the CFTR gene, which is causative in CF)Other (potential implications in diseases that involve CFTR dysfunction)
05

Safety considerations

Potential for off-target effects with ASO therapyLong-term effects of modulating regulatory lncRNAs are unknownImmune stimulation or toxicity from ASO chemistry modifications possible, but generally manageable with chemical backbone modifications
06

Interacting drugs

Antisense oligonucleotides (ASOs)
07

Biomarkers

Levels of CFTR-AS1 (BGas) expression in tissues could act as a pharmacodynamic biomarker for patient stratification or response monitoring in future therapies targeting this lncRNA, but no validated clinical biomarkers are established yet.

Beyond the preview

Go deeper on CFTR antisense RNA 1 (CFTR-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CFTR antisense RNA 1 (CFTR-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call